Profile of Venous Thromboembolism at the Patients with Non-Small Cell Lung Carcinoma

被引:0
作者
Mehic, Bakir [1 ]
Zutic, Hasan [1 ]
Mehic, Amina [2 ]
机构
[1] Univ Sarajevo, Ctr Clin, Clin Lung Dis & TB, Sarajevo 71000, Bosnia & Herceg
[2] Univ Sarajevo, Fac Med, Sarajevo 71000, Bosnia & Herceg
来源
HEALTHMED | 2009年 / 3卷 / 01期
关键词
venous thromboembolism; non-small cell lung cancer; predictive parameters; retrospectively reviewed; RISK-FACTORS; ADENOCARCINOMA; FREQUENCY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although lung cancer incidence has increased during the last decades and non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung tumors, few reports exist on the incidence of (venous thromboembolism) VTE in NSCLS. The purpose of this paper is to try to make definition of predictive parameters for onset of VTE at the patients with NSCLc. Clinical records of all NSCLC patients with VTE, treated at Clinic of Lung Diseases and TB, Clinical Centre University of Sarajevo, from 2006-2008 were retrospectively reviewed. In total there were 1563 patients with NSCLC. Results of the research: Among 1563 hospitalized patients with NSCLC during three years period, 92 (5.88%) were diagnosed with VTE and 0.58% with pulmonary embolism (PE). Mean age of our patients with VTE was 62.8 +/- 8.6 years (range 36-86), and male sex was 3.6 time more frequent than female. After calculating the correlation coefficient, it is evident that there is strong corrleation between performance status (PS) and the time of onset of VTE, and low correlation between the location and the time of the onset VTE, as well as low correlation between PS and the location of the VTE. Conclusion: As predictive parameters for onset of VTE at the patients with NSCLC we could include adenocarcinoma as the most frequent histology type of NSCLC at the cases of VTE (65.2%). Advanced cancer stage (84.8%) could be the significant predictor of appearance of VTE. The biggest percent of patients with VTE (44.56%) had this vascular event before the start of chemotherapy and during the first line treatment with chemotherapy. The most frequent location of VTE was on the veins of legs. Diseases of the heart were the most frequent comorbidity, in 39.13% of cases.
引用
收藏
页码:3 / 7
页数:5
相关论文
共 50 条
  • [31] Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma
    Feng, Fei
    Wang, Bin
    Sun, Xiuxuan
    Zhu, Yumeng
    Tang, Hao
    Nan, Gang
    Wang, Lijuan
    Wu, Bo
    Huhe, Muren
    Liu, Shuangshuang
    Diao, Tengyue
    Hou, Rong
    Zhang, Yang
    Zhang, Zheng
    CANCER BIOLOGY & THERAPY, 2017, 18 (01) : 51 - 62
  • [32] Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
    Icht, Oded
    Leader, Avi
    Batat, Erez
    Yosef, Lilach
    Shochat, Tzippy
    Goldstein, Daniel A.
    Dudnik, Elizabeth
    Spectre, Galia
    Raanani, Pia
    Hammerman, Ariel
    Zer, Alona
    ONCOLOGIST, 2023, 28 (06) : E391 - E396
  • [33] Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinoma
    Pavey, SJ
    Hawson, GAT
    Marsh, NA
    BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (05) : 261 - 267
  • [34] ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial
    Chiari, R.
    Ricciuti, B.
    Landi, L.
    Morelli, A. M.
    Delmonte, A.
    Spitalieri, G.
    Cortinovis, D.
    Facchinetti, F.
    Pilotto, S.
    Verusio, C.
    Chella, A.
    Bonanno, L.
    Galena, D.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S464 - S465
  • [35] Venous thromboembolism risk in patients with lung cancer
    Arslan, Sulhalttin
    Karadayi, Sule
    Ozsahin, Sefa Levent
    Sahin, Ekber
    Akkurt, Ibrahim
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 18 (04): : 305 - 309
  • [36] PROGNOSTIC VALUE OF THE PROTEIC EXPRESSION PROFILE IN LOCALLY ADVANCED NON-SMALL CELL LUNG CARCINOMA
    Morbeck, Igor P.
    Gross, Jefferson L.
    Andrade, Victor
    Fogaroli, Ricardo
    Haddad, Fabio
    Younes, Riad
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S949 - S949
  • [37] Association between epidermal growth factor receptor-tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non-small cell lung cancer
    Byun, Joo-Young
    Aiyeolemi, Ayobami
    Qdaisat, Aiham
    Park, Chanhyun
    CANCER, 2024, 130 (20) : 3412 - 3425
  • [38] EGFR mutation status in a series of Turkish non-small cell lung cancer patients
    Calibasi-Kocal, Gizem
    Amirfallah, Arsalan
    Sever, Tolga
    Unal, Olcun Umit
    Gurel, Duygu
    Oztop, Ilhan
    Ellidokuz, Hulya
    Basbinar, Yasemin
    BIOMEDICAL REPORTS, 2020, 13 (02) : 1 - 9
  • [39] New data for venous thromboembolism in patients with small cell lung cancer: A review
    Dimakakos, Evangelos
    Livanios, Konstantinos
    Gkiozos, Ioannis
    Charpidou, Adriani
    Ntalakou, Eleutheria
    Kainis, Ilias
    Syrigos, Konstantinos
    PHLEBOLOGY, 2018, 33 (08) : 517 - 522
  • [40] HER2 mutations in Chinese patients with non-small cell lung cancer
    Song, Zhengbo
    Yu, Xinmin
    Shi, Zhiyong
    Zhao, Jun
    Zhang, Yiping
    ONCOTARGET, 2016, 7 (47) : 78152 - 78158